Zobrazeno 1 - 10 of 27 pro vyhledávání: '"G. Waxenecker"'
1
Qualification and application of a surface plasmon resonance-based assay for monitoring potential HAHA responses induced after passive administration of a humanized anti Lewis-Y antibody
Autor: Andreas Nechansky, GC Mudde, S. Stranner, I. Zinoecker, G. Himmler, Oliver Szolar, G. Waxenecker
Publikováno v: Journal of Pharmaceutical and Biomedical Analysis. 41:1347-1353
A sensitive, surface plasmon resonance (SPR)-based assay monitoring potential human-anti-human antibody (HAHA) reactions against the monoclonal antibody (mAb) IGN311 is presented. The latter is a fully humanized Lewis-Y carbohydrate specific mAb that
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67b670d69e4f2ceb47d8589eae402052
https://doi.org/10.1016/j.jpba.2006.03.026
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
A phase I/II, open label trial of Lewis Y specific monoclonal antibody IGN311 to evaluate safety and efficacy in patients with malignant effusion
Autor: R. Kircheis, P. Regitnik, W. Weizer, S. Wiederkum, M. Kainer, G. Waxenecker, Thomas Bauernhofer, H. Samonigg, Hans Loibner, B. Lileg
Publikováno v: Journal of Clinical Oncology. 24:2547-2547
2547 Background: Treatment of CRC patients (pts) with the humanized mAb IGN311 targeting the carbohydrate Lewis Y eliminated circulating tumor cells in blood and thereby confirmed the clinical profile of the parent murine antibody ABL364, which showe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2880ae0e56f2192d8a0c7c94dbd1b341
https://doi.org/10.1200/jco.2006.24.18_suppl.2547
Zobrazit plný text záznamu
6
Results from a phase I clinical trial with IGN311, a fully humanized IgG1 antibody against Lewis Y in patients with solid tumors expressing Lewis Y antigen
Autor: G. Mudde, O. Scheiber, S. Stranner, C. Aulmann, G. Waxenecker, N. Eller, Günter Schlimok, O. Obwaller, Daniel Oruzio
Publikováno v: Journal of Clinical Oncology. 22:2624-2624
2624 Background: IGN311 is a humanized monoclonal antibody (mab) binding to Lewis Y, a blood group-related carbohydrate determinant that has been found to be associated with 60–90% of human epithelial carcinomas (ca) incl. breast, colon, gastric an
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::23b2ad0c6fd193186bcfe04d0c0a5beb
https://doi.org/10.1200/jco.2004.22.90140.2624
Zobrazit plný text záznamu
7
A phase Ib trial of an anti-idiotypic vaccine for Lewis Y (IGN 301) administered subcutaneously in patients with refractory solid tumors
Autor: P. Heeger, M. Roddy, Hans Loibner, Paul Elson, Snehal G. Thakkar, G. Himmler, B. Wacker, G. Waxenecker, Ronald M. Bukowski
Publikováno v: Journal of Clinical Oncology. 22:2586-2586
2586 Background: The Lewis Y (LeY) antigen is expressed on 60–90% of solid tumors with limited expression on normal tissue. This property has attracted interest to use LeY antigen as a vaccine in cancer immunotherapy. Use of an anti-idiotypic antib
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f029026778f1636458beaefa7bc7c7ad
https://doi.org/10.1200/jco.2004.22.90140.2586
Zobrazit plný text záznamu
8
[Untitled]
Autor: G. Himmler, Hesso Farhan, Markus Klinger, G. Waxenecker, E Janzek, GC Mudde, Michael Freissmuth, Hans Loibner
Publikováno v: Cancer Cell International. 4:S23
Introduction IGN311 is a humanized monoclonal IgG1 antibody that binds to the Lewis Y (LeY) carbohydrate overexpressed on epithelial cancers. IGN311 potently mediates human effector functions (ADCC, CDC). The overexpression of fucosyltransferases in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3fb06a44a0a0bfec2c0f0e6bee3c1143
https://doi.org/10.1186/1475-2867-4-s1-s23
Zobrazit plný text záznamu
9
[Untitled]
Autor: Susanne Wiederkum, I Froihofer, C. Schwager, H Klug, P Umana, Manfred Schuster, GC Mudde, G. Himmler, Hans Loibner, P Brünker, G. Waxenecker
Publikováno v: Cancer Cell International. 4:S22
Introduction Igeneon is currently testing a humanized monoclonal antibody specific for Lewis Y (IGN311) in clinical trials of passive cancer immunotherapy. The aim of the current study is to enhance the effector function of this antibody by genetical
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::96d9a4064f308b9068fa73989e0b15c1
https://doi.org/10.1186/1475-2867-4-s1-s22
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje